WilliamC.HuangMDFACS (He/Him)

Minimally Invasive Surgery, Surgical Oncology

Professor of Urology and Radiology Vice Chairman (Clinical Affairs), Department of Urology Chief of Urology, Tisch Hospital Co-Director, NYU Robotic Surgery Center NYU Hospitals Center

Join to view full profile

Dr. Huang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huang's full profile

Already have an account?

Office
222 East 41st Street
12th Floor
New York, NY 10017

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2004 - 2007
Lahey ClinicResidency, Urology, 2000 - 2004
Lahey ClinicResidency, Surgery, 1998 - 2000
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1998

Certifications & Licensure

NJ State Medical License 2023 - 2025
NY State Medical License 2004 - 2025
MA State Medical License 2000 - 2004
ME State Medical License Active through 2003
PA State Medical License 2000 - 2002
American Board of Urology Urology
Society of Urologic OncologyFellow

Awards, Honors, & Recognition

America’s Top Doctors for Cancer Castle Connolly, 2018-2021
Top Doctors New York Magazine, 2016, 2018-2021
Regional Top Doctor Castle Connolly, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Active, not recruiting
Phase 3
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

90 citations
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Gopa Iyer, Arjun Vasant Balar, Matthew I. Milowsky, Bernard H. Bochner, Guido Dalbagni
Journal of Clinical Oncology. 2018-05-09
101 citations
Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
James S. Wysock, Neil Mendhiratta, Fabio Zattoni, Xiaosong Meng, Marc A. Bjurlin
BJU International. 2016-10-01
3 citations
Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile.
Victor R Adorno Febles, Yuan Hao, Aarif Ahsan, Jiansheng Wu, Yingzhi Qian
The Prostate. 2023-06-01

Authored Content

Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018

Press Mentions

What 5 Doctors Are Excited About in Kidney Cancer ResearchSeptember 5th, 2024
UroGen Announces New Data from the OPTIMA II Study That Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder CancerDecember 2nd, 2022
KCCure Represents Patients at AUA 2018May 27th, 2018
Join now to see all